Cardiac Glycoside Glucoevatromonoside Induces Cancer Type-Specific Cell Death

• Príomhchruthaitheoirí: Naira F. Z. Schneider (Údar), Claudia Cerella (Údar), Jin-Young Lee (Údar), Aloran Mazumder (Údar), Kyung Rok Kim (Údar), Annelise de Carvalho (Údar), Jennifer Munkert (Údar), Rodrigo M. Pádua (Údar), Wolfgang Kreis (Údar), Kyu-Won Kim (Údar), Christo Christov (Údar), Mario Dicato (Údar), Hyun-Jung Kim (Údar), Byung Woo Han (Údar), Fernão C. Braga (Údar), Cláudia M. O. Simões (Údar), Marc Diederich (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Frontiers Media S.A., 2018-03-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Cardiac glycosides (CGs) are natural compounds used traditionally to treat congestive heart diseases. Recent investigations repositioned CGs as potential anticancer agents. To discover novel cytotoxic CG scaffolds, we selected the cardenolide glucoevatromonoside (GEV) out of 46 CGs for its low nanom...